Summary
Researchers identified twelve bioactive components of the combination of Alpinia officinarum and Cyperus rotundus, known for their use in the treatment of gastric ulcers. The research utilized transcriptomic and metabolomic analyses to explore the mechanisms of action of this combination in ethanol-induced ulcers. The compounds DPHA and galangin proved effective in protecting GES-1 cells against damage, with increased levels after compatibility. The CH2Cl2 fraction of the combination demonstrated a reduction in hemorrhage and infiltration of inflammatory cells in animal models. Western blot analysis suggested that this fraction may regulate proteins such as TRPV1, PI3K, and AKT, involved in the inflammatory response and gastric mucosal protection. These findings reinforce the therapeutic potential of the combination of Alpinia and Cyperus in gastric protection, although more studies are needed to confirm these effects in humans.
Key points
- Twelve bioactive components were identified in the combination of Alpinia officinarum and Cyperus rotundus.
- DPHA and galangin showed significant protection against damage in GES-1 cells.
- The CH2Cl2 fraction reduced hemorrhage and inflammatory infiltration in gastric ulcer models.
- Regulation of the proteins TRPV1, PI3K, and AKT was observed as a mechanism of action.
- The research highlights the importance of compatibility between components to increase efficacy.
✦ For you
If you suffer from gastric discomfort, consider observing how your diet and eating habits affect your well-being. Foods rich in antioxidants and anti-inflammatories, such as ginger and turmeric, may be beneficial. Keep a food diary to identify patterns and reactions. If symptoms persist, seek a qualified healthcare professional.
For practitionersExpand
Consider including Alpinia officinarum and Cyperus rotundus in formulas for patients with a history of gastric ulcers. Assess the compatibility of components to maximize efficacy. Regulation of the proteins TRPV1, PI3K, and AKT may be a focal point in evaluating therapeutic effects.